Albis expands portfolio and invests in Hamburg site

Albis Plastic is expanding its product portfolio to include custom compounds for healthcare applications, the company has announced.

The new products, grouped under the Alcom Med brand are based on different polymers and include both colourings and fillers.

The new compounds come from Albis Plastics’ reaction to new market developments including current changes to regulatory requirements, such as the new European Medical Devices Regulation.

Mike Freudenstein, director of Marketing Healthcare at Albis, said: “We are seeing a continuously growing demand from the processing industry for compounds that both comply with the regulatory requirements and offer customer specific material solutions. Alcom Med means we can guarantee our customers production with strict quality criteria and offer close project support through our experienced healthcare specialists.”

The new brand is also designed to enable a focus on service elements, such as consistent formula, dedicated change management and regulatory support, for example, with regards to the biological evaluation of materials.

Alongside this new brand, Albis is investing in its Hamburg production site by creating an entirely self-contained production line for the manufacture of Alcom Med compounds. The company also has plans to enhance its quality management system by implementing standards and measures in line with applicable quality management systems for medical products.

"Especially the adoption of applicable medical quality standards and processes across the entire value chain provides a practical foundation for us as a compounder and ensures we meet our customers' high standards in the best way and ensure safety and quality in healthcare applications. Our investment will enable us to be flexible even with small quantities whilst also being able to deliver worldwide," Freudenstein added.